Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm. (January 2021)
- Record Type:
- Journal Article
- Title:
- Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm. (January 2021)
- Main Title:
- Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm
- Authors:
- Lee, Yun Young
Park, Hee Ho
Park, Wooram
Kim, Hyelim
Jang, Jong Geol
Hong, Kyung Soo
Lee, Jae-Young
Seo, Hee Seung
Na, Dong Hee
Kim, Tae-Hyung
Choy, Young Bin
Ahn, June Hong
Lee, Wonhwa
Park, Chun Gwon - Abstract:
- Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new strain of coronavirus not previously identified in humans. Globally, the number of confirmed cases and mortality rates of coronavirus disease 2019 (COVID-19) have risen dramatically. Currently, there are no FDA-approved antiviral drugs and there is an urgency to develop treatment strategies that can effectively suppress SARS-CoV-2-mediated cytokine storms, acute respiratory distress syndrome (ARDS), and sepsis. As symptoms progress in patients with SARS-CoV-2 sepsis, elevated amounts of cell-free DNA (cfDNA) are produced, which in turn induce multiple organ failure in these patients. Furthermore, plasma levels of DNase-1 are markedly reduced in SARS-CoV-2 sepsis patients. In this study, we generated recombinant DNase-1-coated polydopamine-poly(ethylene glycol) nanoparticulates (named long-acting DNase-1), and hypothesized that exogenous administration of long-acting DNase-1 may suppress SARS-CoV-2-mediated neutrophil activities and the cytokine storm. Our findings suggest that exogenously administered long-acting nanoparticulate DNase-1 can effectively reduce cfDNA levels and neutrophil activities and may be used as a potential therapeutic intervention for life-threatening SARS-CoV-2-mediated illnesses.
- Is Part Of:
- Biomaterials. Volume 267(2021)
- Journal:
- Biomaterials
- Issue:
- Volume 267(2021)
- Issue Display:
- Volume 267, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 267
- Issue:
- 2021
- Issue Sort Value:
- 2021-0267-2021-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-01
- Subjects:
- COVID-19 -- Sepsis -- DNase -- Nanoparticles -- NETosis
Biomedical materials -- Periodicals
Biocompatible Materials -- Periodicals
Biomatériaux -- Périodiques
610.28 - Journal URLs:
- http://www.sciencedirect.com/science/journal/01429612 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/01429612 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/01429612 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.biomaterials.2020.120389 ↗
- Languages:
- English
- ISSNs:
- 0142-9612
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2087.715000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 23274.xml